

**Biocon Limited**

20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/TG/2026-27/61

August 25, 2026

|                                                                                                                                              |                                                                                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To<br>The Manager,<br><b>BSE Limited</b><br>Department of Corporate Services<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street, Mumbai – 400 001 | To<br>The Manager,<br><b>National Stock Exchange of India Limited</b><br>Corporate Communication Department<br>Exchange Plaza, Bandra Kurla Complex<br>Mumbai – 400 051 |
| <b>Scrip Code - 532523</b>                                                                                                                   | <b>Scrip Symbol - BIOCON</b>                                                                                                                                            |

**Subject: Company Statement**

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. **“Biocon Announces Pegfilgrastim Biosimilar Marketing Approval by Japan Ministry of Health, Labour and Welfare (MHLW)”**.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Rajesh U. Shanoy**  
**Company Secretary and Compliance Officer**  
**M. No.: ACS 16328**

Encl: Company Statement

## NOTIFICATION TO STOCK EXCHANGE

### COMPANY STATEMENT

## **Biocon Announces Pegfilgrastim Biosimilar Marketing Approval by Japan Ministry of Health, Labour and Welfare (MHLW)**

***Bengaluru, Karnataka, India, August 25, 2026***

Biocon Biologics Ltd., a wholly-owned subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), received marketing approval for its pegfilgrastim biosimilar (“Product”) from Japan’s Ministry of Health, Labour and Welfare (MHLW). The product, a biosimilar to Neulasta®, is developed and manufactured by Biocon Biologics Ltd, parent entity of Biocon Biologics UK PLC (Biocon Biologics Ltd and Biocon Biologics UK PLC shall be collectively referred to as “Biocon”), with Global Regulatory Partners Japan serving as the Marketing Authorization Holder on behalf of Biocon. Sandoz K.K. shall exclusively promote, sell, and distribute the Product in Japan.

This approval further strengthens Biocon’s portfolio of biosimilar products in Japan and reaffirms the company’s commitment to increasing patient access to high-quality and affordable medications globally.

– Company Spokesperson

*Neulasta® is a registered trademark of Amgen Inc.*